The Phase I study success could lead to further studies in patients with schizophrenia and other psychosis-related conditions. Credit: Marina Demidiuk/Shutterstock.

NeuShen Therapeutics has dosed the first healthy volunteer in Australia, marking the start of a Phase I first-in-human clinical trial of NS-136 for schizophrenia treatment.

NS-136 is a new selective M4 receptor-positive allosteric modulator (M4 PAM) intended for the treatment of schizophrenia along with other psychosis-associated conditions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Claimed to offer potential benefits in alleviating negative symptoms and cognitive impairment, M4 PAM has the potential to treat psychosis in Alzheimer’s or Parkinson’s disease.

Developed from NeuShen’s small molecule R&D platform, NS-136 has shown efficacy against both positive and negative symptoms of schizophrenia in preclinical animal models.

The Phase I double-blind, placebo-controlled trial is designed to assess the safety and tolerability of NS-136 in healthy participants.

The trial’s success could lead to further studies in patients with schizophrenia and other psychosis-related conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier, NeuShen filed an investigational new drug (IND) application with China’s National Medical Products Administration (NMPA).

NeuShen Therapeutics founder and CEO Dr Joan Shen said: “NS-136 was discovered and developed internally by utilising our profound CNS expertise and advanced AI technology.

“It holds great potential to offer innovative therapies for not only schizophrenia but also a spectrum of cognitive and mood disorders.”

In March 2024, the Center for Drug Evaluation (CDE) of the NMPA approved NeuShen’s IND application for its pipeline product NS-041.